

## Module:

**Biological Foundations of Mental Health**

Week 3:

Synaptic transmission and neurotransmitter systems



Dr Jon Robbins

### Topic 2:

**Neurotransmitters, receptors and pathways**

Part 3 of 4

## Topic list



This week, we will be looking at the following topics:

- Topic 1: Action potentials and synaptic transmission
- **Topic 2: Neurotransmitters, receptors and pathways**
- Topic 3: Neurotransmission defects and mental health; focus on schizophrenia

Click **Next** to continue

# Part 3

## Dopamine

Week 3 Synaptic transmission and neurotransmitter systems

Topic 3: Neurotransmitters, receptors and pathways

3 of 15

## Dopamine

S

S


R

R



R

D

D



### Dopamine



- Monoamine
- Location in CNS

Th - thalamus  
Hyp - hypothalamus  
Am - amygdala  
C - cerebellum  
Sep - septum  
Sn - substantia nigra  
Str - striatum  
P - pituitary  
Ac - nucleus accumbens  
Hip - hippocampus

Humphrey et al (2014)

Week 3 Synaptic transmission and neurotransmitter systems

Topic 3: Neurotransmitters, receptors and pathways

4 of 15

## Dopamine – synthesis

S

S

R

R

R

D

D

**Dopamine synthesis**

Tyrosine (diet)



Tyrosine hydroxylase (rate limiting)

DOPA



Dopa decarboxylase

DOPAMINE

DOPA - dihydroxyphenylamine

Week 3 Synaptic transmission and neurotransmitter systems

Topic 3: Neurotransmitters, receptors and pathways

5 of 15

## Dopamine – storage

S

S

R

R


R

D

D

**Dopamine storage**

● VMAT1  
● VMAT2



VMAT - vesicular monoamine transporter  
1 or 2 can be cell type specific

Week 3 Synaptic transmission and neurotransmitter systems

Topic 3: Neurotransmitters, receptors and pathways

6 of 15

## Dopamine – release

S

S

R

R

R


D

D

## Dopamine release

Dopamine has a **calcium dependent vesicular release** which mainly occurs at the **axon end terminal bouton**.

Dopamine can also be released in an **en passant** manner, where small **release sites** are located all the way down the axon, meaning that dopamine can be released **at all these points**.



Week 3 Synaptic transmission and neurotransmitter systems

Topic 3: Neurotransmitters, receptors and pathways

7 of 15

## Dopamine – receptors

S

S

R

R

R

D

D

## Dopamine receptors



- All GPCRs (Class A, rhodopsin-like)
- 'D1-like' D1, D5 coupled to Gs
- 'D2-like' D2, D3, D4 coupled to Go/Gi

Week 3 Synaptic transmission and neurotransmitter systems

Topic 3: Neurotransmitters, receptors and pathways

8 of 15

## Dopamine- reuptake

S

S

R


R

R

D

D

## Dopamine reuptake



Week 3 Synaptic transmission and neurotransmitter systems

Topic 3: Neurotransmitters, receptors and pathways

9 of 15

## Dopamine – degradation

S

S

R


R

R

D

D

## Dopamine degradation



Week 3 Synaptic transmission and neurotransmitter systems

Topic 3: Neurotransmitters, receptors and pathways

10 of 15

## Dopamine – drugs

S

S

R

R

R

D

D

**Dopamine: drugs****Synthesis** - Levodopa**Storage** - reserpine, methamphetamine**Release** – amantadine**Receptors:**

- full agonist - DA, apomorphine, bromocriptine
- competitive antagonists - haloperidol, chlorpromazine

**Reuptake** – cocaine, bupropion, methylphenidate (Ritalin)**Degradation:**

- MAO inhibitors - phenelzine, selegiline (MAO-B)
- COMT inhibitors – entacapone, tolcapone

## Dopamine – disease

S

S

R

R

R

D

D

**Dopamine: disease**

Cocaine, amphetamines and bromocriptine (a fungal contamination of grain) interfere with the dopaminergic system.



Parkinson's, schizophrenia, hormonal disturbances and drug dependence all involve dopamine.



Dopamine is involved in motor control and pituitary control, and may be involved in reward system and thought.

## Dopamine – fact sheet

**Dopamine: fact sheet****Drugs**

<b>S</b>	Tyrosine hydroxylase	L-DOPA
<b>S</b>	Vesicular	Methamphetamine
<b>R</b>	Calcium dependent terminal and en passant	Amantadine
<b>R</b>	DA receptors – GPCR (five subtypes)	Apomorphine Haloperidol Chlorpromazine
<b>R</b>	DAT	Methylphenidate
<b>D</b>	MAO & COMT	Selegiline Tolcapone

Clinical use

## References

- Chapter 39 Rang et al (2016) Pharmacology 8<sup>th</sup> ed
- Humphrey, P. R., Maureen, M. D., & Ritter, J. M. (Eds.). (2012). Rang & Dale's pharmacology. Elsevier.
- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=20>

# End of Part 3